Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Despite the high costs of treatment of people with kidney disease and associated comorbid conditions, the amount of reliable information available to guide the care of such patients is very limited. Some treatments have been assessed in randomized trials, but most such trials have been too small to detect treatment effects of a magnitude that would be realistic to achieve with a single intervention. Therefore, KDIGO convened an international, multidisciplinary controversies conference titled "Challenges in the Conduct of Clinical Trials in Nephrology" to identify the key barriers to conducting trials in patients with kidney disease. The conference began with plenary talks focusing on the key areas of discussion that included appropriate trial design (covering identification and evaluation of kidney and nonkidney disease outcomes) and sensible trial execution (with particular emphasis on streamlining both design and conduct). Break out group discussions followed in which the key areas of agreement and remaining controversy were identified. Here we summarize the main findings from the conference and set out a range of potential solutions. If followed, these solutions could ensure future trials among people with kidney disease are sufficiently robust to provide reliable answers and are not constrained by inappropriate complexities in design or conduct.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Self-citationLevey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Self-citationEgger, M., & Smith, G. D. (1995) · BMJ · doi:10.1136/bmj.310.6982.752 · Cited by 508
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Lambers Heerspink, H. J., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070688 · Cited by 242
Cited by
Levey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.06.009 · Cited by 591
Self-citationInternational consensus definitions of clinical trial outcomes for kidney failure: 2020
Levin, A., Agarwal, R., Herrington, W. G., Heerspink, H. L., Mann, J. F. E., Shahinfar, S., Tuttle, K. R., Donner, J.-A., Jha, V., Nangaku, M., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.07.013 · Cited by 125
“These definitions will support continued efforts to ensure that future clinical trials are comparable, robust, and streamlined.(11,28) Attendees appreciated that irrespective of the final definitions, there will be situations in which modifications are justified or necessary.”
BackgroundSelf-citationDesign, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Wanner, C., Green, J. B., Hauske, S. J., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac040 · Cited by 110
“Advantages included a semiquantitative assessment of feasibility at each prospective site, which provided early confirmation that recruitment of 6000 participants from only eight countries was possible, and decreased the likelihood of screening failures [41, 42].”
Self-citationDawson, J., Campbell, K. L., Craig, J. C., Tong, A., Teixeira-Pinto, A., Brown, M. A., Howard, K., Howell, M., Khalid, R., Sud, K., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.11.015 · Cited by 49
Self-citation
Metadata
- Authors
- Baigent, C., Herrington, W. G., Coresh, J., Landray, M. J., Levin, A., Perkovic, V., Pfeffer, M. A., Rossing, P., Walsh, M., Wanner, C., Wheeler, D. C., Winkelmayer, W. C., McMurray, J. J. V., Abu-Alfa, A., Archdeacon, P., Block, G. A., Caskey, F. J., Cheung, A. K., Cooper, B., Craig, J. C., Dember, L. M., Eknoyan, G., Gansevoort, R. T., Gill, J. S., Gillespie, B., Greene, T., Harris, D. C., Haynes, R., Hemmelgarn, B. R., Herzog, C. A., Hiemstra, T. F., Inker, L. A., Jardine, M. J., Jha, V., Jiang, L., Johansen, K. L., Kewalramani, R., Lambers Heerspink, H. J., Lefkowitz, M., Lok, C. E., Loud, F., Mačiulaitis, R., Maddux, D. W., Maddux, F. W., Madero, M., Mariz, S., Mauer, M., Nally, J. V., Nangaku, M., Okpechi, I. G., Parfrey, P. S., Pecoits-Filho, R., Pereira, B. J. G., Rocco, M. V., Rossignol, P., Schaefer, F., Tentori, F., Thompson, A., Tonelli, M., Tong, A., Toto, R. D., Tuttle, K. R., Vetter, T., Moon Wang, A. Y., & Zannad, F.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 92
- Issue
- 2
- Pages
- 297-305
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2735667632
- Cited by
- 146
- References
- 6
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.